Coya Therapeutics sees success in early COYA-302 FTD trial, aims for Phase 2b in H2 2025 and ALS filing in Q2 2025. Read why ...

One continuing challenge is the need to suppress transplant patients' immune systems to prevent their bodies from rejecting ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

Stephanie Thompson of Ottawa was in her early 40s when she began noticing the first signs of amyotrophic lateral sclerosis (ALS). The now 44-year-old was experiencing “weird muscle cramps” that would ...